Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
With one gene therapy for hemophilia B well along the way in the clinic at Spark Therapeutics, pharma giant Pfizer $PFE is now extending …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
